FUJIFILM Diosynth Biotechnologies– tag –
-
Lonza, Sartorius, and FUJIFILM Diosynth Bolster Biopharmaceutical Manufacturing Capacity, Highlighting Single-Use Technology as Key
SNS Insider Unknown Overview This article highlights the biopharmaceutical manufacturing capacity expansions by Lonza Group, Sartorius, and FUJIFILM Diosynth Biotechnologies, as noted in the "Biopharmaceutical Fermentation Market" report... -
Gene Therapy Manufacturing: Viral Vector CDMOs Confront Oversupply Amidst Rapid Expansion
IntuitionLabs USA Overview A recent industry report offers a comparative analysis of the AAV and lentiviral vector CDMO market, revealing trends of consolidation and emerging capacity oversupply. It highlights key players like FUJIFILM D... -
Fujifilm Diosynth Commits $2 Billion to North Carolina Gene Therapy Facility Amid Supply Chain Shifts; India Emerges as Key CDMO Hub
BioSpace Global Overview Fujifilm Diosynth is investing approximately $2 billion in a new gene therapy manufacturing facility in North Carolina, strategically positioning against global supply chain shifts. Catalent, under Novo Holdings,... -
Japan Prioritizes Quality in ‘China Plus One’ CDMO Strategy with Over $4 Billion Investment by FUJIFILM Diosynth and Others
BioProcess International USA Overview A BioProcess International article analyzes the 'China Plus One' strategy and biomanufacturing capacity in the APAC region. FUJIFILM Diosynth Biotechnologies has committed over $4 billion to global e... -
Global Pharma and Biotech Firms Intensify Investment in Biologics Contract Manufacturing Market, openPR.com Reports
openPR.com USA Overview Global pharmaceutical and biotechnology companies are significantly increasing their investments in the biologics contract manufacturing (CDMO) market, as reported by openPR.com. FUJIFILM Diosynth Biotechnologies ... -
SNS Insider Analysis: Viral Vector Manufacturing Market Surges as Leading CDMOs Expand Capacity with Advanced AAV and Lentiviral Technologies
SNS Insider India Overview SNS Insider's market overview highlights that the increasing number of gene therapy clinical trials and the reliance on CDMOs are driving growth in the viral vector manufacturing market. Key CDMOs like Fujifilm... -
Pharmaceutical CDMO Market Report: Capital Investments and Advanced Therapies Drive Growth
Global Market Insights Global Overview This article provides an overview of the Pharmaceutical CDMO Market research report published by Global Market Insights. The report highlights significant capital investments and major expansions wi... -
Denmark Fortifies Biomanufacturing Leadership with $239M AGC Biologics Investment
GeneOnline デンマーク Overview Denmark is rapidly consolidating its position as a global biomanufacturing powerhouse, attracting substantial investment in its advanced infrastructure. AGC Biologics has committed $239 million to significa... -
Fujifilm Diosynth Biotechnologies Strengthens Technological Leadership in Cell Culture, Microbial Fermentation, Viral Vectors, and Cell Therapy Manufacturing
MabDesign France Overview Fujifilm Diosynth Biotechnologies is focused on combining its technological leadership with cGMP manufacturing facilities across key areas: cell culture, microbial fermentation, viral vectors, and cell therapy. ... -
US Policy Shift Reshapes Biomanufacturing Supply Chain: Fujifilm Diosynth, Japan Government Drive Asia’s Rise as Key Hub
BioProcess Insider USA Overview The U.S. policy pivot regarding China's biotechnology sector is driving a global biomanufacturing supply chain restructuring. Fujifilm Diosynth Biotechnologies is pursuing over $4 billion in global expansi...
12